TR200103396T2 - Anti-fas antikoru içeren farmasötik terkipler. - Google Patents

Anti-fas antikoru içeren farmasötik terkipler.

Info

Publication number
TR200103396T2
TR200103396T2 TR2001/03396T TR200103396T TR200103396T2 TR 200103396 T2 TR200103396 T2 TR 200103396T2 TR 2001/03396 T TR2001/03396 T TR 2001/03396T TR 200103396 T TR200103396 T TR 200103396T TR 200103396 T2 TR200103396 T2 TR 200103396T2
Authority
TR
Turkey
Prior art keywords
pharmaceutical compositions
compositions containing
containing anti
fas antibody
fas
Prior art date
Application number
TR2001/03396T
Other languages
English (en)
Inventor
Serizawa Nobufusa
Ichikawa Kimihisa
Yoshida Hiroko
Original Assignee
Sankyo Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Company Limited filed Critical Sankyo Company Limited
Publication of TR200103396T2 publication Critical patent/TR200103396T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Bu bulus, bir otoimmün hastaligin veya romatizmal artritin profilaksisi ve/veya tretmani için yeni bir farmasötik terkiple ilgilidir.
TR2001/03396T 1999-05-24 2000-05-24 Anti-fas antikoru içeren farmasötik terkipler. TR200103396T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14303399 1999-05-24

Publications (1)

Publication Number Publication Date
TR200103396T2 true TR200103396T2 (tr) 2002-04-22

Family

ID=15329357

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03396T TR200103396T2 (tr) 1999-05-24 2000-05-24 Anti-fas antikoru içeren farmasötik terkipler.

Country Status (19)

Country Link
US (1) US6746673B2 (tr)
EP (1) EP1180369A4 (tr)
KR (1) KR20020008197A (tr)
CN (1) CN1191861C (tr)
AU (1) AU761544C (tr)
BR (1) BR0010909A (tr)
CA (1) CA2373992A1 (tr)
CZ (1) CZ20014181A3 (tr)
HK (1) HK1042049A1 (tr)
HU (1) HUP0201333A3 (tr)
IL (1) IL146566A0 (tr)
MX (1) MXPA01012206A (tr)
NO (1) NO20015711L (tr)
NZ (1) NZ515598A (tr)
PL (1) PL352159A1 (tr)
RU (1) RU2222347C2 (tr)
TR (1) TR200103396T2 (tr)
WO (1) WO2000071160A1 (tr)
ZA (1) ZA200109575B (tr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1087993E (pt) 1998-06-18 2008-07-04 Imed Ab Péptidos fas e anticorpos para modular a apoptose
CA2452986C (en) * 2001-07-02 2011-11-01 Aimsco Limited Use of polyclonal anti-hiv goat serum as a therapeutic agent
GB0201896D0 (en) * 2002-01-28 2002-03-13 Ice Biolog Ltd Treatment
PE20030340A1 (es) * 2001-08-28 2003-04-05 Sankyo Co Metodo para el tratamiento o prevencion de desgaste oseo
JP2005532261A (ja) * 2002-01-28 2005-10-27 エイムスコ・リミテッド 治療
US6989386B2 (en) * 2002-04-30 2006-01-24 Dana-Farber Cancer Institute Pharmaceutically active ornithine derivatives, ammonium salts thereof and methods of making same
TW200400830A (en) * 2002-06-07 2004-01-16 Sankyo Co A pharmaceutical composition used in the treatment of bone erosion
US20050032807A1 (en) * 2003-08-06 2005-02-10 Rosenwald Lindsay A. Methods of treating inflammatory diseases with ammonium salts of ornitihine derivatives
GB0427568D0 (en) * 2004-12-16 2005-01-19 Resolution Chemicals Ltd Particle-size reduction apparatus, and the use thereof
US8052971B2 (en) * 2005-11-21 2011-11-08 MG Biologics Oral use of specific antibodies for intestinal health
CN101092417B (zh) * 2006-06-19 2011-04-27 上海金色医药科技发展有限公司 一种叶酸类似物及用于医疗的叶酸类似物的盐
HUE044398T2 (hu) * 2007-10-08 2019-10-28 Medicines For Malaria Venture Mmv Flexibilis oldalláncokat tartalmazó maláriaellenes vegyületek
AU2009259906B2 (en) 2008-06-20 2016-06-16 Massachusetts Institute Of Technology Methods to identify macromolecule binding and aggregation prone regions in proteins and uses therefor
CN102625813A (zh) 2008-06-20 2012-08-01 诺华公司 具有降低的聚集的免疫球蛋白
US8377444B2 (en) * 2008-08-01 2013-02-19 Axis Inc. Therapeutic agent or preventive agent for osteoarthritis
ES2643446T3 (es) * 2009-06-04 2017-11-22 Novartis Ag Métodos para la identificación de sitios para conjugación de IgG
EP2266984A1 (en) * 2009-06-26 2010-12-29 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Pyrido[2,3-d]pyrimidines as Wnt antagonists for treatment of cancer and arthritis
KR101138460B1 (ko) 2009-10-12 2012-04-26 한국생명공학연구원 항-ｆａｓｎ 자가면역 항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
WO2011046309A2 (en) * 2009-10-12 2011-04-21 Korea Research Institute Of Bioscience And Biotechnology A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof
WO2014022817A2 (en) 2012-08-03 2014-02-06 Novartis Ag Methods to identify amino acid residues involved in macromolecular binding and uses therefor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3062268D1 (en) * 1979-06-14 1983-04-14 Wellcome Found Alkoxybenzylpyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof
ZA861235B (en) * 1985-03-08 1986-10-29 Univ Princeton Pyrido(2,3-d)pyrimidine derivatives
DE3603577A1 (de) * 1986-02-06 1987-08-13 Joachim K Prof Dr Seydel Neue substituierte 2,4-diamino-5-benzylpyrimidine, deren herstellung und deren verwendung als arzneimittel mit antibakterieller wirksamkeit
NO169490C (no) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
JPH02237935A (ja) 1989-03-10 1990-09-20 Bio Kagaku Kenkyusho:Kk エイズ処置剤
US5008391A (en) * 1989-07-07 1991-04-16 Eli Lilly And Company Enantioselective synthesis of antifolates
US4996207A (en) * 1990-01-18 1991-02-26 Nair Madhavan G Three new non-polyglutamatable deazaaminopterins
WO1991010448A1 (en) 1990-01-19 1991-07-25 German Cancer Research Center A cell surface antigen associated with cellular apoptosis
CA2071205C (en) 1990-01-19 2000-03-14 Peter H. Krammer Cell surface antigen associated with cellular apoptosis
CA2095518A1 (en) * 1990-11-14 1992-05-15 Jeffrey M. Blaney Specific inhibition of dihydrofolate reductase and compounds therefor
AU3276793A (en) * 1991-12-20 1993-07-28 Agouron Pharmaceuticals, Inc. Antifolate quinazolines
US5877176A (en) * 1991-12-26 1999-03-02 Cornell Research Foundation, Inc. Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
US5426110A (en) * 1993-10-06 1995-06-20 Eli Lilly And Company Pyrimidinyl-glutamic acid derivatives
CA2158822C (en) * 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
US5952499A (en) * 1995-01-16 1999-09-14 Commonwealth Scientific And Industrial Research Organisation Therapeutic compound-fatty acid conjugates
US6221615B1 (en) * 1995-05-12 2001-04-24 Apoptosis Technology, Inc. Peptides and compositions which modulate apoptosis
US6004942A (en) * 1995-08-30 1999-12-21 The Regents Of The University Of California Methods for treating arthritis by administering an apoptosis regulator
AU1942497A (en) * 1996-03-19 1997-10-10 Chugai Seiyaku Kabushiki Kaisha Uveitis remedy
US6544523B1 (en) * 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6001962A (en) * 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
IL123756A0 (en) * 1997-03-21 1998-10-30 Sankyo Co Humanized anti-human FAS antibody
IL123888A0 (en) * 1997-04-01 1998-10-30 Sankyo Co Anti-fas antibodies
US6098631A (en) * 1998-01-21 2000-08-08 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disease

Also Published As

Publication number Publication date
IL146566A0 (en) 2002-07-25
CA2373992A1 (en) 2000-11-30
NZ515598A (en) 2004-05-28
AU761544C (en) 2004-02-12
BR0010909A (pt) 2002-02-19
MXPA01012206A (es) 2002-06-21
KR20020008197A (ko) 2002-01-29
RU2222347C2 (ru) 2004-01-27
AU4948600A (en) 2000-12-12
WO2000071160A1 (fr) 2000-11-30
AU761544B2 (en) 2003-06-05
ZA200109575B (en) 2003-04-30
CN1191861C (zh) 2005-03-09
HUP0201333A2 (en) 2002-08-28
US6746673B2 (en) 2004-06-08
HK1042049A1 (zh) 2002-08-02
CN1364090A (zh) 2002-08-14
PL352159A1 (en) 2003-07-28
NO20015711D0 (no) 2001-11-23
EP1180369A4 (en) 2002-07-24
HUP0201333A3 (en) 2004-11-29
CZ20014181A3 (cs) 2002-03-13
NO20015711L (no) 2002-01-11
US20020103212A1 (en) 2002-08-01
EP1180369A1 (en) 2002-02-20

Similar Documents

Publication Publication Date Title
TR200103396T2 (tr) Anti-fas antikoru içeren farmasötik terkipler.
TR200001218T2 (tr) İkameli karboksamidotiazoller, bunların üretimi ve bunları içeren farmasötik bileşimler.
TR200200768T2 (tr) Yeni kuinüklidin türevleri ve bunu içeren ilaç bileşimleri
TR200101961T2 (tr) 1,2-halkalı kinolin türevleri
TR200401264T4 (tr) CB1-reseptör-antagonistiyle-sibütramin birleşimi, bunları içeren farmasötik-bileşimler ve obezite tedavisinde kullanımları.
TR200101858T2 (tr) JNK protein kinaz inhibitörleri olarak 4-ariloksindoller
TR200001012T2 (tr) Yeni ariloksi-alkil-dialkilaminler.
TR199901710T2 (tr) IL-8 reseptör antagonistleri.
ATE288893T1 (de) Polymorphe form von atorvastatin-calcium
ATE314371T1 (de) Spiro-indole als y5-rezeptor antagonisten
MA30345B1 (fr) Formulation d'anticorps monoclonal humain anti-igf-1r
BR9911724A (pt) Ciclosporina que tem um perfil de atividade melhorado
TR200101772T2 (tr) IL-8 Reseptörü antagonistleri olarak hidroksi difenil üre sülfonamidler
TR200002877T2 (tr) Sülfonamid türevleri
PT1109812E (pt) Pirrolobenzodiazepinas
SE9802729D0 (sv) Novel Compounds
TR199900318T2 (tr) IL-8 reseptör antagonistleri.
DK0705100T3 (da) Terapeutiske substituerede guanidiner
TR200200982T2 (tr) Farmasötik bileşim terkipleri.
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
TR200101756T2 (tr) Protein kinaz inhibitörleri olarak 4,5-pirazinoksindoller.
TR200100455T2 (tr) Nimesulid içeren topikal farmasötik bileşimler
TR200200359T2 (tr) Cgrp Antagonist'lerinin ve cgrp-release (Gevşeme)-Engelleyici Menopoza Bağlı Deri Kızarıklıklarında Kullanılması
SE9901077D0 (sv) Novel use
SE9804212D0 (sv) Compounds